Burrill & Company The managing director of Burrill & Company discusses the biotech industry in Taiwan, the various hurdles the market faces and why there is so much potential for industry growth in Taiwan. During the six years that you have been with Burrill, you have mostly covered the Greater China region. What…
Clinical trials TaiGen is on the brink of releasing Taiwan’s first innovative drug. In this interview, the Chairman and CEO of the company discusses the development path the company chose to take, and explains the decision to market the drug first in China. Nemonoxacin will be the first-ever pharmaceutical developed in this…
Government Regulation You have been in Taiwan now for ten months. What are the most important characteristics of this market from your perspective, and what surprised you most about Taiwan? Taiwan is a highly developed economy to start with; it is a very established market, with a very good healthcare system. The…
Generics In the first part of this two-part interview, the Chairman of TTY Biopharm considers the success of his long-term strategy to streamline TTY’s portfolio and focus on the company’s strengths, and talks about the opportunities in Asia for companies that have followed a similar path to TTY. To read the…
Hsinchu Science Park The Director General of one of the world’s most successful science parks discusses the history of the park, the reasons behind its incredible success, the unique set-up of the park which allows its administation board to act as a one-stop shop for tenants in terms of regulation and approvals, and…
investment The CEO of MaRS Innovation, a commercialization incubator created by 16 of Toronto’s best research institutions and supported by the government, assesses Toronto’s merits as an innovation hub, and describes several successful case studies of the way in which MaRS Innovation has helped to commercialize ideas in the pharmaceutical and…
Generics A perspective on Indonesia’s booming market for contraceptive products from Hendra Gunawan, managing director of PT Tunggal Idaman Abdi, one of Indonesia’s leading players in the sector. To cope with the growing demand for contraceptive driven by 65 million women of reproductive age, the company is building a second hormone…
Clinical trials The chairman and CEO of Medigen shares his insights on a significant past three years for the company, which included both an IPO and major developments for the company’s innovative molecule PI-88. He also offers his perspective on the increasing synergies between Taiwan and China in the biotech sector. During our…
canada foundation for innovation Tell us about the Canada Foundation for Innovation (CFI) – where does Canada fit on the world stage of innovation and how are you ensuring Canada stands out as a top destination for innovation today? The Canada Foundation for Innovation (CFI) funds research infrastructure. The organization was created in…
P&G Singapore Innovation Center (SgIC) Why did P&G decide to set up the center in Singapore? There are several reasons why P&G decided on Singapore. First, we wanted to reach more consumers, particularly in emerging markets; Singapore is very central to that. From Singapore we can reach 2/3 of the world’s population within a 6…
convatec Convatec acquired Boston Medical Device in September 2011. Which have been the major challenges following the acquisition, and which synergies are to be expected? The story of BMD would suffice for several volumes, as it has been a long and winding road. We have experienced several transitions in the last…
Department of Industry Would you outline the commitment of the Ministry to foster a positive business environment for the Australian pharmaceutical industry to prosper? Issues faced by the pharmaceutical industry are not unlike those in many other industries and the high value of our dollar has brought a sharp focus to industry productivity…
See our Cookie Privacy Policy Here
